Navigation Links
Predicting acute GVHD by gene expression could improve liver stem cell transplant outcomes

Tampa, Fla. (July 21, 2008) Many cell transplants involve the use of stem cells from another human being (known as an allograft), which raises the major concern of the potential for acute graft-versus-host disease (GVHD). GVHD occurs when an immune response is elicited by the grafted cells against the recipient, resulting in tissue damage for the treated individual.

Presently, there are no definitive markers for predicting the development of acute graft-versus-host disease (GVHD) or its progression following the transplant of allogenic stem cells as therapy for liver cancer.

However, in a study published in the current issue CELL TRANSPLANTATON (17:5), researchers at the University of Florida offer a preliminary "molecular signature" based on gene expression for the development of acute GVHD following allogenic hematopoietic stem cell transplants (HSCT).

Despite immunosuppressive drugs, acute GVHD can develop within 100 days post-transplant. Where tissue damage in the skin, liver and gastrointestinal tract is extensive, prognosis can be poor. Although clinicians can identify a well-defined pathophysiological mechanism for acute graft-versus-host disease (GVHD), being able to uncover molecular markers for a patient's potential to develop GVHD would be a significant breakthrough.

"Our study enrolled four acute GVHD patients and four acute GVHD-free patients and noted significant differences in the expression of 1,658 genes between the control and acute GVHD patients," explained Vijay Reddy, MD, PhD, the study's lead author.

Of the 1,658 genes observed, immune-related genes showed the greatest amount of change.

"We observed a predominately pro-inflammatory gene expression profile in acute GVHD patients, consistent with our knowledge of how GVHD develops," concluded Reddy. "Perhaps the most valuable finding was having discovered the possible role for IL-27, IL-22 and Th17 cellular inflammatory responses in the development of acute GVHD."

Future research, said Reddy and colleagues, may want to address gene expression profiling of acute GVHD immediately after noting clinical symptoms, yet before immunosuppressive drugs are administered.

"Nevertheless, this is an important study to help develop biomarkers for determining who is at risk for GVHD following current and future stem cell treatments," said Dr. Paul Sanberg, Distinguished Professor at University of South Florida Health and coeditor-in-chief of Cell Transplantation.


Contact: Vijay Reddy, MD, PhD
Cell Transplantation Center of Excellence for Aging and Brain Repair

Related biology news :

1. Trial seeks genetic fingerprint for predicting drug effectiveness
2. Predicting growth hormone treatment success
3. Predicting the radiation risk to ESAs astronauts
4. Predicting the perfect predator
5. Predicting the distribution of creatures great and small
6. Tolerance to inhalants may be caused by changes in gene expression
7. Unique pattern of gene expression can indicate acetaminophen overdose
8. Powerful integration of lipid metabolic profiling with gene expression analysis
9. Gene-environment interaction in yeast gene expression
10. Scientists discover small RNAs that regulate gene expression and protect the genome
11. Newly created cancer stem cells could aid breast cancer research
Post Your Comments:
(Date:11/19/2015)... 19, 2015  Based on its in-depth analysis of ... BIO-key with the 2015 Global Frost & Sullivan Award ... Sullivan presents this award to the company that has ... needs of the market it serves. The award recognizes ... expands on customer base demands, the overall impact it ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... 2015  Vigilant Solutions announces today that Mr. ... Directors. --> --> ... the partnership at TPG Capital, one of the largest ... Billion in revenue.  He founded and led TPG,s Operating ... companies, from 1997 to 2013.  In his first role, ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , ... November 25, 2015 , ... ... uBiome, were featured on AngelList early in their initial angel funding process. Now, ... syndicate for individuals looking to make early stage investments in the microbiome space. ...
(Date:11/24/2015)... 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ... New York on Wednesday, December 2 at 9:30 ... president and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim ... provide a corporate overview. --> th Annual Oppenheimer ...
(Date:11/24/2015)... CITY , Nov. 24, 2015 /PRNewswire/ - Aeterna ... request of IIROC on behalf of the Toronto Stock ... news release there are no corporate developments that would ... --> --> About ... . --> Aeterna Zentaris is ...
(Date:11/24/2015)... ... November 24, 2015 , ... The Academy of Model Aeronautics ... (SIG), MultiGP, also known as Multirotor Grand Prix, to represent the First–Person View (FPV) ... Many AMA members have embraced this type of racing and several new model aviation ...
Breaking Biology Technology: